Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma

NCT00923936 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

NIH

Sponsor class

Conditions

Sarcoma, Kaposi

Interventions

DRUG: Liposomal Doxorubicin
DRUG: Bevacizumab

Sponsor

National Cancer Institute (NCI)